Edgewise Therapeutics, Inc. (EWTX)Healthcare | Biotechnology | Boulder, United States | NasdaqGS
32.45 USD
-1.52
(-4.475%) ⇩
(April 21, 2026, 4 p.m.
EDT)
After hours: 32.45 Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 18, 2026, 11:25 p.m. EDT
Imminent upside breakout play targeting $35.00 given near-term call wall at 35.0 and consistent recent price strength above the 50-day MA. Fundamentals remain leveraged (negative earnings, high risk profile) but short-term price action is the primary driver here; buy the wave without expecting a multiple expansion immediately. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.039354 |
| AutoARIMA | 0.051664 |
| AutoETS | 0.051667 |
| MSTL | 0.053850 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.524 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.764 |
| Market Cap | 3,480,928,512 |
| Forward P/E | -13.87 |
| Beta | 0.25 |
| Website | https://edgewisetx.com |
As of April 18, 2026, 11:25 p.m. EDT: Call flow is overwhelmingly bullish, characterized by massive volume at near-term strikes (34.0 and 35.0) and significant open interest at the 35.0 strike, suggesting a stop-profit move or barrier level if price approaches $35.00. Puts are largely idle with negligible volume compared to calls. The asymmetric positioning (high call volume/OITM, low put activity) indicates speculators are positioning for continued upside momentum in the immediate weeks.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5107169 |
| Address1 | 1,715 38th Street |
| All Time High | 40.49 |
| All Time Low | 5.12 |
| Ask | 32.59 |
| Ask Size | 7 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 751,490 |
| Average Daily Volume3 Month | 869,354 |
| Average Volume | 869,354 |
| Average Volume10Days | 751,490 |
| Beta | 0.247 |
| Bid | 32.23 |
| Bid Size | 7 |
| Board Risk | 8 |
| Book Value | 4.915 |
| City | Boulder |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 32.45 |
| Current Ratio | 19.853 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 34.115 |
| Day Low | 32.09 |
| Debt To Equity | 0.764 |
| Display Name | Edgewise Therapeutics |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -189,322,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -16.469 |
| Enterprise Value | 3,117,860,608 |
| Eps Current Year | -2.06917 |
| Eps Forward | -2.33987 |
| Eps Trailing Twelve Months | -1.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.8574 |
| Fifty Day Average Change | 1.5925999 |
| Fifty Day Average Change Percent | 0.051611602 |
| Fifty Two Week Change Percent | 151.07169 |
| Fifty Two Week High | 35.0 |
| Fifty Two Week High Change | -2.5499992 |
| Fifty Two Week High Change Percent | -0.07285712 |
| Fifty Two Week Low | 12.15 |
| Fifty Two Week Low Change | 20.300001 |
| Fifty Two Week Low Change Percent | 1.6707821 |
| Fifty Two Week Range | 12.15 - 35.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,616,765,400,000 |
| Float Shares | 67,616,900 |
| Forward Eps | -2.33987 |
| Forward P E | -13.868292 |
| Free Cashflow | -87,337,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 146 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00445 |
| Held Percent Institutions | 1.16011 |
| Implied Shares Outstanding | 107,270,521 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-03-26 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado. |
| Long Name | Edgewise Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,480,928,512 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_595539666 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -167,795,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,643,979,598 |
| Number Of Analyst Opinions | 12 |
| Open | 33.95 |
| Operating Cashflow | -143,816,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 720 262 7002 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 32.45 |
| Post Market Time | 1,776,807,395 |
| Previous Close | 33.97 |
| Price Eps Current Year | -15.682617 |
| Price Hint | 2 |
| Price To Book | 6.602238 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.368 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.5200005 |
| Regular Market Change Percent | -4.4745374 |
| Regular Market Day High | 34.115 |
| Regular Market Day Low | 32.09 |
| Regular Market Day Range | 32.09 - 34.115 |
| Regular Market Open | 33.95 |
| Regular Market Previous Close | 33.97 |
| Regular Market Price | 32.45 |
| Regular Market Time | 1,776,801,600 |
| Regular Market Volume | 673,938 |
| Return On Assets | -0.23018 |
| Return On Equity | -0.34192002 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 107,270,521 |
| Shares Percent Shares Out | 0.0881 |
| Shares Short | 9,448,351 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,484,539 |
| Short Name | Edgewise Therapeutics, Inc. |
| Short Percent Of Float | 0.1031 |
| Short Ratio | 10.7 |
| Source Interval | 15 |
| State | CO |
| Symbol | EWTX |
| Target High Price | 51.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 41.08333 |
| Target Median Price | 45.0 |
| Total Cash | 530,108,992 |
| Total Cash Per Share | 4.942 |
| Total Debt | 3,990,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.7953 |
| Two Hundred Day Average Change | 10.654701 |
| Two Hundred Day Average Change Percent | 0.48885316 |
| Type Disp | Equity |
| Volume | 673,938 |
| Website | https://edgewisetx.com |
| Zip | 80,301 |